According to a report by the Financial Center, TSMC (2330) was once hailed as the strongest 'guardian mountain' of the Taiwan stock market. However, as AI semiconductor technologies advance, some scholars believe the biotech industry could become the next 'mountain of guardianship' following semiconductors. Unfortunately, with the recent failure of the breast cancer drug trials by the biotech firm Hau-Ting, the chairman of Financial Media, Hsieh Chin-Ho, pessimistically described this as a reflection of a 'decade-long dream of biotechnology'. Hau-Ting's stock, which soared to NT$755, has now plummeted to NT$35, highlighting the risks of a bubble in the biotech sector.

In his Facebook post, Hsieh recounted the tumultuous journey of multiple biotech companies over the past decade, once igniting a wave of purchases in the market, now plunged to a trough. He specifically pointed out that another company, Giya, saw its stock price crash from NT$486 to NT$23.65. However, amidst this bubble, a few biotech companies such as Boryung have defied the trend and continued to thrive, presenting a rare positive case.